CoChat
Sign Up
Cited by 1,249Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis MechanismsCerebral Venous Sinus Thrombosis

The DOI matches its Crossref record; 205 of the 208 references it cites were found in a registry or an index.

Antithrombotic Therapy for Venous Thromboembolic Disease

Büller, Harry R., Agnelli, Giancarlo, Hull, Russel D., Hyers, Thomas M., Prins, Martin H., Raskob, Gary E.·2004·Chest
DOI 10.1378/chest.126.3_suppl.401s
Open this paper in CoChat — free account

Abstract

This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key recommendations in this chapter are the following: for patients with objectively confirmed deep vein thrombosis (DVT), we recommend short-term treatment with subcutaneous (SC) low molecular weight heparin (LMWH) or, alternatively, IV unfractionated heparin (UFH) [both Grade 1A]. For patients with a high clinical suspicion of DVT, we recommend treatment with anticoagulants while awaiting the outcome of diagnostic tests (Grade 1C+). In acute DVT, we recommend initial treatment with LMWH or UFH for at least 5 days (Grade 1C), initiation of vitamin K antagonist (VKA) together with LMWH or UFH on the first treatment day, and discontinuation of heparin when the international normalized ratio (INR) is stable and > 2.0 (Grade 1A). For the duration and intensity of treatment for acute DVT of the leg, the recommendations include the following: for patients with a first episode of DVT secondary to a transient (reversible) risk factor, we recommend long-term treatment with a VKA for 3 months over treatment for shorter periods (Grade 1A). For patients with a first episode of idiopathic DVT, we recommend treatment with a VKA for at least 6 to 12 months (Grade 1A). We recommend that the dose of VKA be adjusted to maintain a target INR of 2.5 (INR range, 2.0 to 3.0) for all treatment durations (Grade 1A). We recommend against high-intensity VKA therapy (INR range, 3.1 to 4.0) [Grade 1A] and against low-intensity therapy (INR range, 1.5 to 1.9) compared to INR range of 2.0 to 3.0 (Grade 1A). For the prevention of the postthrombotic syndrome, we recommend the use of an elastic compression stocking (Grade 1A). For patients with objectively confirmed nonmassive PE, we recommend acute treatment with SC LMWH or, alternatively, IV UFH (both Grade 1A). For most patients with pulmonary embolism (PE), we recommend clinicians not use systemic thrombolytic therapy (Grade 1A). For the duration and intensity of treatment for PE, the recommendations are similar to those for DVT.

Overview

Integrity signals

Registry

Crossref · 10.1378/chest.126.3_suppl.401s

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 7

  1. Hull, 2002, A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract], Blood, 100, 148a
  2. Hull, 2001, Safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal-vein thrombosis using subcutaneous low-molecular-weight heparin versus warfarin [abstract], Thromb Haemost
  3. Hull, 2003, A randomised trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer [abstract], Thromb Haemost, P137a
  4. Prandoni, 2002, Below-knee compression stockings for prevention of the post-thrombotic syndrome: a randomized study [abstract], Pathophysiol Haemost Thromb, 32, 72
  5. Morl, 1986, Treatment of postthrombotic syndrome with a mixture of enzymes [in German], Therapiewoche, 36, 2443
  6. Massoure, 2000, Thromboses veineuses profondes des members supérieurs, J Mal Vasc, 25, 250
  7. Pegis, 1997, Thrombolyse in situ dans le traitement des thromboses veineuses d'effort du membre supérieur, J Mal Vasc, 22, 187

Cited by

Sorted by citations

See all 1,249

Related

See all

Metadata

Authors
Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E.
Venue
Chest
Publisher
Elsevier BV
Published
2004-09
Volume
126
Issue
3
Pages
401S-428S
ISSN
0012-3692 (ISSN-L)
DOI
10.1378/chest.126.3_suppl.401s
OpenAlex
W2134355273
Cited by
1,249
References
208
Citations by year
2025: 4 · 2024: 2 · 2023: 2 · 2022: 7 · 2021: 8 · 2020: 9 · 2019: 13 · 2018: 15 · 2017: 17 · 2016: 32 · 2015: 25 · 2014: 25 · 2013: 41 · 2012: 54
FWCI
121.06
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • CHEST Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
Keywords
venous thromboembolism, antithrombotic therapy, deep vein thrombosis, pulmonary embolism, low molecular weight heparin, unfractionated heparin, vitamin K antagonists, anticoagulation duration, post-thrombotic syndrome, compression stockings, thrombolysis, thromboprophylaxis
MeSH terms
Fibrinolytic Agents, Heparin, Heparin, Low-Molecular-Weight, Humans, Long-Term Care, Pulmonary Embolism, Vitamin K, Randomized Controlled Trials as Topic, Evidence-Based Medicine, International Normalized Ratio, Venous Thrombosis, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review